AMLX - NASDAQ
Amylyx Pharmaceuticals, Inc.
$13.61
+2.4%Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotAmylyx Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Amylyx Pharmaceuticals, Inc. Balance Sheet
AMLX • NASDAQ
| Amylyx Pharmaceuticals, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
226.7M | 77.4M | 170.2M | 62.5M | 50.2M | 12.9M | 3.1M | |
90.3M | 99.1M | 201.2M | 284.4M | 45.9M | 0.0 | 0.0 | |
317M | 176.5M | 371.4M | 346.9M | 96.1M | 12.9M | 3.1M | |
88K | 447K | 40.1M | 15.3M | 0.0 | 0.0 | 0.0 | |
88K | 447K | 40.1M | 15.3M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 38.3M | 9.8M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 5.4M | 762K | 111K | |
6.6M | 12.5M | 14.9M | 10.1M | 3.4M | 0.0 | 26K | |
323.7M | 189.4M | 464.7M | 382.1M | 105M | 13.6M | 3.2M | |
NON-CURRENT ASSETS | |||||||
5.5M | 2.7M | 6.4M | 8.1M | 474K | 151K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 189K | 0.0 | |
3.5M | 1.5M | 46.4M | 1.2M | 189K | 125K | 18K | |
9M | 4.2M | 52.8M | 9.3M | 663K | 465K | 18K | |
332.6M | 193.6M | 517.5M | 391.5M | 105.6M | 14.1M | 3.2M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
3.5M | 2.9M | 22.1M | 6.3M | 4.4M | 3.6M | 2.2M | |
3.5M | 2.9M | 22.1M | 6.3M | 4.4M | 3.6M | 2.2M | |
0.0 | 14M | 16.8M | 23.1M | 8.7M | 3.7M | 1.7M | |
1.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 1.5M | 2.3M | 2M | 0.0 | 0.0 | 0.0 | |
17.9M | 10M | 40.9M | 15.2M | 4.3M | 0.0 | 652K | |
22.7M | 28.4M | 82M | 46.6M | 17.4M | 7.3M | 4.5M | |
NON-CURRENT LIABILITIES | |||||||
4.7M | 0.0 | 0.0 | 0.0 | 0.0 | 1.4M | 14.9M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14K | 4K | |
0.0 | 0.0 | 0.0 | 0.0 | 239.4M | 72.1M | 9.1M | |
4.7M | 463K | 2M | 4.2M | 239.4M | 73.5M | 24M | |
0.0 | 2M | 4.2M | 6.3M | 0.0 | 0.0 | 0.0 | |
27.4M | 28.9M | 84M | 50.8M | 256.8M | 80.8M | 28.6M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 72.1M | 0.0 | |
11K | 7K | 7K | 7K | 1K | 1K | 1K | |
0.0 | 771.5M | 738.2M | 694.9M | 4.7M | 1.2M | 276K | |
-751.4M | -606.7M | -304.9M | -354.2M | -155.8M | -67.9M | -25.6M | |
404K | -92K | 197K | -86K | 9K | -72.1M | 0.0 | |
1.1B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
305.3M | 164.8M | 433.4M | 340.6M | -151.2M | -66.7M | -25.4M | |
305.3M | 164.8M | 433.4M | 340.6M | -151.2M | -66.7M | -25.4M | |
SUMMARY | |||||||
332.6M | 193.6M | 517.5M | 391.5M | 105.6M | 14.1M | 3.2M | |
90.3M | 99.1M | 201.2M | 284.4M | 45.9M | 189K | 0.0 | |
6M | 2M | 4.2M | 6.3M | 0.0 | 1.4M | 14.9M | |
-220.7M | -75.4M | -166M | -56.2M | -50.2M | -11.5M | 11.9M | |
93,323,390 | 93,323,390 | 93,323,390 | 93,323,390 | 93,323,390 | 93,323,390 | 93,323,390 |
SEC Filings
AMLX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 10, 2025 | September 09, 2025 | 2025 |
Related Guides
Continue your AMLX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.